A Phase I Study of DNL758 in Healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Aug 2019
Price : $35 *
At a glance
- Drugs DNL 758 (Primary)
- Indications Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Sanofi
- 05 Aug 2019 According to a Denali Therapeutics media release, Sanofi has commenced dosing of DNL758 in this trial.
- 05 Aug 2019 Status changed from planning to recruiting according to a Denali Therapeutics media release
- 11 Nov 2018 New trial record